Wong, Chi Heem
Li, Dexin
Wang, Nina
Gruber, Jonathan
Lo, Andrew W.
Conti, Rena M. http://orcid.org/0000-0002-4190-1839
Article History
Received: 20 August 2022
Revised: 20 July 2023
Accepted: 18 August 2023
First Online: 8 November 2023
Competing interests
: CW, DL, and NW report no conflicts. RMC has no conflicts of interest to declare. JG reports no conflicts. JG is a consultant for both the insurer Aetna, Inc. and for the biotech company Sarepta, Inc. During the most recent 6-month period JG has received compensation from Aetna, MacMillan Publishing, and Access Health, International. AL reports personal investments in private biotech companies, biotech venture capital funds, and mutual funds. AL is a co-founder and partner of QLS Advisors, a healthcare analytics and consulting company; an advisor to Apricity Health, Aracari Bio, BrightEdge Impact Fund, Enable Medicine, Inc, FINRA, Health at Scale, Lazard, MIT Proto Ventures, Quantile Health, Roivant Social Ventures, SalioGen Therapeutics, Swiss Finance Institute, Thalēs, and xCures; a director of AbCellera, Annual Reviews, Atomwise, BridgeBio Pharma, Uncommon Cures, and Vesalius. During the most recent six-year period (beginning 2017), AL received speaking/consulting fees, honoraria, or other forms of compensation from: AbCellera, AlphaSimplex Group, Annual Reviews, Apricity Health, Aracari Bio, Atomwise, Bernstein Fabozzi Jacobs Levy Award, BridgeBio, Cambridge Associates, Chicago Mercantile Exchange, Enable Medicine, Financial Times Prize, Harvard Kennedy School, IMF, Journal of Investment Management, Lazard, National Bank of Belgium, New Frontier Advisors/Markowitz Award, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Quantile Health, Research Affiliates, Roivant Sciences, SalioGen, Swiss Finance Institute, and WW Norton.